Schwab Charles Investment Management Inc. grew its stake in G1 Therapeutics Inc (NASDAQ:GTHX) by 48.8% in the second quarter, Holdings Channel reports. The institutional investor owned 43,000 shares of the company’s stock after buying an additional 14,100 shares during the period. Schwab Charles Investment Management Inc.’s holdings in G1 Therapeutics were worth $1,869,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. TD Asset Management Inc. raised its holdings in shares of G1 Therapeutics by 26.4% in the second quarter. TD Asset Management Inc. now owns 32,668 shares of the company’s stock worth $1,420,000 after buying an additional 6,832 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of G1 Therapeutics by 64.6% in the first quarter. California State Teachers Retirement System now owns 20,576 shares of the company’s stock worth $762,000 after buying an additional 8,076 shares during the last quarter. Strs Ohio raised its holdings in shares of G1 Therapeutics by 78.3% in the second quarter. Strs Ohio now owns 4,100 shares of the company’s stock worth $178,000 after buying an additional 1,800 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new position in shares of G1 Therapeutics in the second quarter worth $317,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of G1 Therapeutics by 1,313.5% in the first quarter. JPMorgan Chase & Co. now owns 221,555 shares of the company’s stock worth $8,209,000 after buying an additional 205,881 shares during the last quarter. 69.17% of the stock is owned by institutional investors and hedge funds.

GTHX has been the subject of a number of research analyst reports. BidaskClub cut shares of G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 19th. Needham & Company LLC raised their price target on shares of G1 Therapeutics to $76.00 and gave the stock a “buy” rating in a report on Tuesday, September 18th. HC Wainwright reaffirmed a “buy” rating and issued a $79.00 price target on shares of G1 Therapeutics in a report on Monday, September 17th. BTIG Research initiated coverage on shares of G1 Therapeutics in a report on Monday, September 10th. They issued a “buy” rating and a $80.00 price target for the company. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $74.50.

In other news, insider Mark A. Velleca sold 5,000 shares of the stock in a transaction on Monday, July 16th. The shares were sold at an average price of $42.06, for a total value of $210,300.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Seth Rudnick sold 10,000 shares of the stock in a transaction on Monday, August 6th. The stock was sold at an average price of $50.69, for a total transaction of $506,900.00. The disclosure for this sale can be found here. Insiders sold 66,583 shares of company stock worth $3,617,196 in the last quarter. Company insiders own 15.92% of the company’s stock.

NASDAQ:GTHX opened at $42.98 on Friday. The firm has a market capitalization of $1.75 billion, a PE ratio of -12.04 and a beta of -1.02. G1 Therapeutics Inc has a 1-year low of $18.03 and a 1-year high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.01. Research analysts forecast that G1 Therapeutics Inc will post -2.68 EPS for the current fiscal year.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Story: What is a Stop Order?

Want to see what other hedge funds are holding GTHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for G1 Therapeutics Inc (NASDAQ:GTHX).

Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.